Discussion
cardiovascular morbidities, thromboembolic, postoperative blood loss, bleeding
BLEEDING, WOUND INFECTION, ADVERSE EFFECTS, POSTOPERATIVE FEVER, INTRAOPERATIVE BLOOD LOSS, EVENTS
This RCT indicated that oxytocin and TA with ethamsylate had no significant value in lowering intraoperative blood loss compared with the placebo for abdominal myomectomy. Also, the changes in both HB and HCT values showed no significant differences between the three groups. Non-significant trends were observed for a reduction in operation time, intra/postoperative blood transfusion, hospital stay, postoperative fever, and wound infection.Our results contrasted with a prior RCT conducted on the Egyptian population. They found that women assigned to get TA and ethamsylate instead of oxytocin experienced substantially less intraoperative blood loss during myomectomy [Furthermore, two recent systematic reviews and meta-analyses found that prophylactic TA was associated with considerable decreases in total, intra, and postoperative blood loss compared to the placebo for women undergoing myomectomy [Concerning HB and HCT levels, our study was in line with two previous analyses that showed that in comparison to the control group, preventive TA and oxytocin were linked to a considerable reduction in postoperative HB and HCT [Despite that, a preventative TA was associated with a considerably shorter hospital stay following myomectomy in a prior study; there was no evident difference in the operating time and blood transfusion rate between the intervention and placebo, which is consistent with our findings [All the perioperative therapies discussed above have self-limited adverse effects regarding safety outcomes. Although these events are discovered to be extremely low. TA is generally safe; however, intravenous TA is believed to raise the risk of thromboembolic and cardiovascular morbidities [Compared to GnRH analogs, the most common approach for lowering myomectomy bleeding, TA and ethamsylate, are less expensive [